Moderna vs Sarepta Therapeutics
Moderna and Sarepta Therapeutics are similar in size: $1.94bn and $2.20bn of revenue in their latest fiscal years. Sarepta Therapeutics grew faster (15.6% against -39.9%). Sarepta Therapeutics kept more of each dollar of sales as profit: a net margin of -32.5% against -145.2%. Moderna carries less debt relative to equity (6.8% against 72.7%).
| Latest fiscal year | ModernaMRNA, 2025 | Sarepta TherapeuticsSRPT, 2025 |
|---|---|---|
| Revenue | $1.94bn | $2.20bn |
| Revenue growth | -39.9% | 15.6% |
| Net income | −$2.82bn | −$713m |
| Operating margin | -158.1% | -31.8% |
| Net margin | -145.2% | -32.5% |
| Return on equity | -28.9% | -53.5% |
| Free cash flow | −$2.06bn | −$307m |
| Cash | $2.60bn | $801m |
| Total debt | $590m | $829m |
| Debt to equity | 6.8% | 72.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $2.0m | $25.0m |
| Employees | 4,700 | 835 |
| Market value | $90.21bn | $1.96bn |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 22 sales | 0 buys, 2 sales |